Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease

Fig. 5

Sacubitril/valsartan improved expression of Sirt1/PGC-1α in DKD mice and HG HK-2 cells. (A, B) Representative western blotting images and densitometric analysis of Sirt1 and PGC1α in kidney from mice. (C, D) Representative western blotting images and densitometric analysis of Sirt1 and PGC1α in HK-2 cells. (E) PCR analysis of Sirt1 and PGC1α mRNA expression in HK-2 cells treated with HG. (F) Representative images and statistical graphs of immunofluorescent staining for Sirt1 in HK-2 cells from different groups. Results represent means ± SEM, n = 4. *P < 0.05, **P < 0.01, ***P < 0.001. DKD, Diabetic kidney disease; Val, DKD + Valsartan treated; Sac/Val, DKD + Sacubitril/Valsartan treated; NC, normal control; HM, high mannitol; HG, high glucose; HG + Val, high glucose + Valsartan; HG + LBQ/Val, high glucose + LBQ657 + valsartan

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us